Surgical Science Sweden ABSUSRF -2.20%82 Altman Z2-Score is 13.78 as of Jun. 26, 2026, which is 34% above its 10-year median of 10.31. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 678 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 95.87% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Surgical Science Sweden AB has a Altman Z2-Score of 13.78, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Surgical Science Sweden AB's Altman Z2-Score or its related term are showing as below:
SUSRF'
s Altman Z2-Score Range Over the Past 10 Years
Min: -0.39 Med: 10.31 Max: 15.11
Current: 13.78
During the past 11 years, Surgical Science Sweden AB's highest Altman Z2-Score was 15.11. The lowest was -0.39. And the median was 10.31.
Surgical Science Sweden AB (OTCPK:SUSRF) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUSRF vs VEEV, BTSG, TEM: Altman Z2-Score Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Altman Z2-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Altman Z2-Score falls into.
Surgical Science Sweden AB Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Surgical Science Sweden AB (SUSRF) has a Altman Z2-Score of 13.78 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Surgical Science Sweden AB and its competitors. This is 34% above median its historical median of 10.31. According to the industry distribution chart, Surgical Science Sweden AB ranks #28 out of 678 companies in the Healthcare Providers & Services industry, placing it in the top 4.1%.
Is Surgical Science Sweden AB's Altman Z2-Score too high?
Surgical Science Sweden AB's current Altman Z2-Score of 13.78 is 34% above median its 10-year median of 10.31. The Healthcare Providers & Services industry median Altman Z2-Score is 2.17. Surgical Science Sweden AB's value of 13.78 is 536.5% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #28 out of 678 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Altman Z2-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #28 out of 678 companies for Altman Z2-Score. This places Surgical Science Sweden AB in the top 4% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 2.17. Surgical Science Sweden AB's value of 13.78 is 536.5% above this benchmark. While the company's 10-year median is 10.31 vs. the industry median of 2.17, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Healthcare Providers & Services company?
The median Altman Z2-Score among Healthcare Providers & Services companies is 2.17, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Altman Z2-Score of 13.78 is 536.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Altman Z2-Score is 2.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Altman Z2-Score is 13.78, which is 34% above median its own 10-year median of 10.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current Altman Z2-Score is 13.78, which is 34% above median its 10-year median of 10.31 and 536.5% above the Healthcare Providers & Services industry median of 2.17. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Altman Z2-Score is 13.78 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Altman Z2-Score: 13.78 (34% above median its 10-year median of 10.31)
GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
Industry Position: 536.5% above the Healthcare Providers & Services median (#28 of 678)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
